Propagermanium monotherapy in patients with relapsed or refractory cancer.
Phase 2
- Conditions
- relapsed or refractory cancer.
- Registration Number
- JPRN-UMIN000030948
- Lead Sponsor
- Hyogo College of Medicine, Institute for Advanced Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1) active lesion of the other type of cancer, except of gastric and head/neck cancer 2) Immunotherapy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method